Publications

Probity Medical Research has compiled journals, articles and presentations for your personal review. Please use the search features below to find an article.

 

If you would like to request an article for personal review please complete the registration form. These publications are for personal use only and cannot be distributed. 

Register

 

Already granted access to an article?  

Login

 

If you cannot find the article you are looking for please contact Probity Medical Research. 

Journals, Articles and Presentations

Found 38 matches.
Page:
3
Refine your search to narrow the results.

Long-Term Safety of Ustekinumab: 5 Years of Follow-up From the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis

Presented at EULAR Annual European Congress of Rheumatology, Madrid, Spain, Jun 12-15, 2013

Condition
Psoriasis, Psoriatic Arthritis
Author
K. Papp, C.E.M. Griffiths, K. Gordon, M. Lebwohl, P.O. Szapary, Y. Wasfi, D. Chan, Y.K. Shen, V. Ho, P.D. Ghislain, B. Strober, K. Reich, on behalf of the PHOENIX 1, 2, and ACCEPT Investigators
Year
2013
Register & Request Access

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Lancet. 2013 Jun 12. pii: S0140-6736(13)60594-2. doi: 10.1016/S0140-6736(13)60594-2. [Epub ahead of print]

Journal
Lancet
PubMed ID
23769296
Condition
Psoriatic Arthritis
Author
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluis Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn, Mittie K Doyle, on behalf of the PSUMMIT 1 Study Group
Year
2013
Register & Request Access

Antagonists of IL12-23 and IL-23

Presented at the 4th Congress of the Psoriasis International Network, Paris, France, July 4-6, 2013

Condition
Psoriasis
Author
Kim Alexander Papp
Year
2013
Register & Request Access

PSOLAR: Global Update of a Multicentre, Open Registry of Psoriasis Patients

Presented at the 4th Congress of the Psoriasis International Network, Paris, France, July 4-6, 2013

Condition
Psoriasis
Author
K. Papp, M. Augustin, B. Strober, V. Ho, S. Fakharzadeh, S. Calabro, W. Langhoiff, M. Chevrier, and on behalf of the PSOLAR Steering Committee
Year
2013
Register & Request Access

Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations

Presented at the 4th Congress of the Psoriasis International Network, Paris, France, July 4-6, 2013

Condition
Psoriasis
Author
C. Leonardi, D. Fiorentino, R. Kalb, M. Chevrier, on behalf of the PSOLAR Steering Committee
Year
2013
Register & Request Access

Major Adverse Cardiovascular Events (MACE) in The Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations

Presented at the 4th Congress of the Psoriasis International Network, Paris, France, July 4-6, 2013

Condition
Psoriasis
Author
L. Naldi, A.B. Gottlieb, F. Kerdel, R. Bissonnette, S. Fakharzadeh, S. Calabro, W. Langholff, and M. Chevrier on behalf of the PSOLAR Steering Committee
Year
2013
Register & Request Access

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

British Journal of Dermatology 2013 Jul;169(1):137-45. doi: 10.1111/bjd.12266.

Journal
British Journal of Dermatology (BJD)
PubMed ID
23387374
Condition
Psoriasis
Author
W.C. Ports, S. Khan, S. Lan, M. Lamba, C. Bolduc, R. Bissonnette and K. Papp
Year
2013
Register & Request Access

Biologic Therapies in Psoriasis: Evaluating the Reasons for Discontinuation in Clinical Practice

Latin American Journal of Psoriasis and Psoriatic Arthritis Aug 2013; 3(8):30-39.

Journal
Revista Latinoamericana de Psoriasis y Artritis Psoriásica (Latin American Journal of Psoriasis and Psoriatic Arthritis)
Condition
Psoriasis and Psoriatic Arthritis
Author
Rachel Vale, Megan Hogan, Kayi Li, Michael Jiaravuthisan, Jensen Yeung
Year
2013
Register & Request Access

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

Health and Quality of Life Outcomes 2013 May 10;11:82. doi: 10.1186/1477-7525-11-82.

Journal
Health and Quality of Life Outcomes
PubMed ID
23663752
Condition
Psoriasis
Author
Vibeke Strand, David Fiorentino, ChiaChi Hu, Robert M Day, Randall M Stevens, Kim A Papp
Year
2013
Register & Request Access

Maintenance of Clinical Response With Long-Term Brodalumab (AMG 827) Therapy for Psoriasis: Week 96 Results From an Open-Label Extension Study

Presented at European Academy of Dermatology & Venereology (EADV), Istanbul, Turkey, October 2-6, 2013

Condition
Psoriasis
Author
K Papp, C Leonardi, A Menter, J-P Ortonne, EHZ Thompson, CE Milmont, A Nirula, P Klekotka
Year
2013
Register & Request Access
Page:
3

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login